NASDAQ:ONVO

Organovo - ONVO Stock Forecast, Price & News

$1.54

+0.02 (+1.32%)

(As of 12/8/2022 10:56 AM ET)

Add

Compare

Today's Range: $1.54
▼
$1.54
50-Day Range: $1.47
▼
$2.17
52-Week Range: $1.45
▼
$5.20

Volume: 1 shs
Average Volume: 15,840 shs
Market Capitalization: $13.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Organovo (NASDAQ:ONVO) Stock

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Stock News Headlines

December 1, 2022 | americanbankingnews.com

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

October 25, 2022 | finance.yahoo.com

Organovo Holdings, Inc. (ONVO)

October 17, 2022 | finance.yahoo.com

Trends in 3D-Printing Materials Technology and the Global Market for the Most Promising New 3D-Printing Materials Applications - Yahoo Finance

October 12, 2022 | benzinga.com

Human Liver Models Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | D - Benzinga

October 9, 2022 | globenewswire.com

3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market - GlobeNewswire

October 3, 2022 | seekingalpha.com

ARKG: Too Hard To Pin Down, Too Volatile For Comfort (BATS:ARKG) - Seeking Alpha

September 30, 2022 | businesswire.com

Global Human Liver Model Market Report 2022: Emerging 3D and 2D Trends in Modeling Human Liver Disease in Vitro Fuel Growth - ResearchAndMarkets.com - Business Wire

September 29, 2022 | businesswire.com

3D Bioprinting Global Market Report 2022: Long-term Forecasts to 2026 & 2031 Featuring Organovo Holdings, Allevi, Cellink, Aspect Biosystems, & 3D Systems - ResearchAndMarkets.com - Business Wire

September 23, 2022 | benzinga.com

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket - American Vir - Benzinga

September 22, 2022 | uk.investing.com

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UK

September 16, 2022 | nasdaq.com

Pre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - Nasdaq

September 16, 2022 | uk.investing.com

Why Applied Optoelectronics Is Trading Higher By Around 31%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UK

September 14, 2022 | rttnews.com

Pre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - RTTNews

September 6, 2022 | globenewswire.com

Organovo to Participate in the H.C. Wainwright 24th Annual - GlobeNewswire

September 6, 2022 | globenewswire.com

Organovo Announces Postponement of Annual Meeting of Stockholders - GlobeNewswire

September 6, 2022 | finance.yahoo.com

Organovo Announces Postponement of Annual Meeting of Stockholders

September 6, 2022 | finance.yahoo.com

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022 | benzinga.com

(AHI), (ALNA) – Why DWAC Is Trading Lower By Around 19%; Here Are 32 Stocks Moving Premarket - Benzinga

September 5, 2022 | finance.yahoo.com

USD 1.18 billion Growth in Human Organoids Market with 44% of the Contribution from North America - Technavio - Yahoo Finance

August 30, 2022 | globenewswire.com

Industrial 3D Printing Market Expected to Reach $107.7 Billion By 2031: Allied Market Research - GlobeNewswire

August 12, 2022 | finance.yahoo.com

Global 4D Printing Market is Predicted to Grow at a CAGR of ~40% during 2022-2031; Increasing Adoption of Novel 4D Printing in Biomedical Sciences such as Prostheses to Elevate Growth - Research Nester - Yahoo Finance

July 28, 2022 | globenewswire.com

By 2028, Demand for Global 3D Printing in Healthcare Market Size to Surpass US$ 3120.06 Million, at a 19.02% CAGR Growth: Comprehensive Research Report by Facts & Factors - GlobeNewswire

July 20, 2022 | finance.yahoo.com

The Global Human Organoids Market is expected to grow by $ 1.18 bn during 2022-2026, accelerating at a CAGR of 16.9% during the forecast period - Yahoo Finance

July 20, 2022 | uk.finance.yahoo.com

The Global Human Organoids Market is expected to grow by $ 1.18 bn during 2022-2026, accelerating at a CAGR of 16.9% during the forecast period - Yahoo Finance UK

July 19, 2022 | finance.yahoo.com

Outlook on the 3D Printing Software and Services Global Market to 2031 - Cost-Effectiveness, Greater Design Flexibility, and Low Wastage are Driving Growth - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Company Calendar

Last Earnings: 8/08/2019
Today: 12/08/2022
Next Earnings (Estimated): 2/13/2023
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ONVO
CUSIP: N/A
CIK: 1497253
Web: www.organovo.com
Phone: (858) 224-1000
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,450,000.00
Net Margins: N/A
Pretax Margin: -757.32%
Return on Equity: -41.86%
Return on Assets: -37.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.54
Quick Ratio: 17.54

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 8.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.47 per share
Price / Book: 0.44

Miscellaneous

Outstanding Shares: 8,710,000
Free Float: 8,364,000
Market Cap: $13.41 million
Optionable: Optionable
Beta: 1.02

Key Executives

Mr. Keith E. Murphy (Age 50)
Exec. Chairman
Comp: $496.77k

Dr. Jeffrey N. Miner (Age 60)
Chief Scientific Officer
Comp: $303.75k

Mr. Thomas Einar Jurgensen J.D. (Age 65)
MS, Gen. Counsel & Corp. Sec.
Comp: $548.03k

Ms. Vaidehi Joshi (Age 36)
Director of Discovery Biology & Director
Comp: $4.42k

Mr. Thomas P. Hess CPA (Age 58)
MBA, Pres & CFO

Dr. Curtis M. Tyree Ph.D.
Sr. VP of Strategy & Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ONVO Stock - Frequently Asked Questions

How have ONVO shares performed in 2022?: Organovo's stock was trading at $3.63 at the beginning of the year. Since then, ONVO shares have decreased by 57.6% and is now trading at $1.54.
View the best growth stocks for 2022 here.
When is Organovo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our ONVO earnings forecast.
How were Organovo's earnings last quarter?: Organovo Holdings, Inc. (NASDAQ:ONVO) posted its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.77 million.
When did Organovo's stock split?: Shares of Organovo reverse split before market open on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What is Taylor Crouch's approval rating as Organovo's CEO?: 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).
What is Organovo's stock symbol?: Organovo trades on the NASDAQ under the ticker symbol "ONVO."
Who are Organovo's major shareholders?: Organovo's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.25%), ARK Investment Management LLC (3.16%), Renaissance Technologies LLC (1.38%) and Virtu Financial LLC (0.17%).
View institutional ownership trends.
How do I buy shares of Organovo?: Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Organovo's stock price today?: One share of ONVO stock can currently be purchased for approximately $1.54.
How much money does Organovo make?: Organovo (NASDAQ:ONVO) has a market capitalization of $13.41 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.
How can I contact Organovo?: Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com.

This page (NASDAQ:ONVO) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial